Abstract -From a large series of 5-substituted 1-(2-deoxy--D-ribofuranosyl)-uracil (dUrd) , 1-(2-deoxy--D-ribofuranosyl)-cytosine (dCyd) and 1-(-D-arabinofuranosyl)-uracil (araU) analogues that have been evaluated for their antiviral properties, the (E)-5-(2-bromovinyl)derivatives emerged as the most potent and most selective antiherpes agents. (E)-5-(2-Bromovinyl)-dUrd (BVDU) and its congeners, (E)-5-(2-bromovinyl)-dCyd (BVDC) and (E)-5-(2-bromovinyl)-araU (BVaraU) , inhibited the replication of herpes simplex virus type I (HSVI) and varicella-zoster virus (VZV) in cell culture at a concentration which was about 5,000-to 50,000-fold lower than the concentration required to affect normal cell growth or metabolism. For example, BVDU inhibited HSV1 replication in primary rabbit kidney cells and VZV in human embryonic lung cells at a concentration of 0.007 pg/ml (0.02 iM) and 0.003 pg/ml (0.01 pM), respectively. A series of sugar-modified analogues and 3'-O-or 5'-Oacyl esters of BVDU have been prepared, and some of these derivatives, i.e. 3'-amino-BVDU and 5'-O-aminoacetyl-BVDU, proved almost as active as BVDU itself. Further studies revealed that the activity spectrum of BVDU includes, in addition to IISVI and VZV, several other herpesviruses such as pseudorabies virus, bovid herpesvirus type 1, simian varicella virus, herpesvirus saimiri and nuclear polyhedrosis virus. Its antiviral action would depend on a specific phosphorylation by the virusencoded thymidine kinase, a preferential inhibition of the viral DNA polymerase by the 5'-triphosphate of BVDU (BVDUTP), and, finally, the incorporation of BVDUTP into viral DNA. BVDU has demonstrated high efficacy in several animal model infections, and preliminary clinical studies point to the great promise of BVDU in the topical and systemic (i.e. oral) treatment of HSVI and VZV infections in humans.
INTRODUCTION
In view of the close resemblance between the metabolic pathways that underlie virus replication and normal cell growth, it has for a long time been considered too formidable a task to design antiviral agents that would eliminate the virus without affecting normal cell metabolism. This prejudice is not longer tenable now that new compounds have been developed which selectively act against herpesvirus replication without danger for the normal cell. Foremost among these selective antiherpes agents are acyclovir (ACV, acycloguanosine, 9-(2-hydroxyethoxymethyl)guanine) (Ref. ACV, BVDU and FIAC are selective inhibitors of herpes simplex virus (HSV) and varicellazoster virus (VZV), and their selectivity depends primarily on a specific phosphorylation by the virus-induced deoxythymidine-deoxycytidine (dThd-dCyd) kinase which limits their further action to the virus-infected cell. Thus, ACV, BVDU and FIAC are particularly effective against those herpesviruses that code for a dThd-dCyd kinase which recognizes the drugs as substrate. Viruses that do not induce such dThd-dCyd kinase are, as a rule, not susceptible to the inhibitory effects of ACV, BVDU or FIAC.
It is remarkable that the majority of the antiviral drugs that have been licensed for clinical use or are being considered for clinical use are directed toward herpesviruses (HSV, Abbreviations. ID50, inhibitory dose-SO; HSVi, herpes simplex virus type I; HSV2, herpes simplex virus type 2; VZV, varicella-zoster virus; PRV, pseudorabies virus; BHVi, bovid herpesvirus type I; SVV, simian varicella virus; HVS, herpesvirus saimiri; NPV, nuclear polyhedrosis virus; VV, vaccinia virus; PRK, primary rabbit kidney (cells); FL, feline lung (cells); HEF, human embryo fibroblast (cells); MO, murine fibroblast (cells); Vero, African green monkey kidney (cells); BilK, baby hamster kidney (cells); MDBK, Madin-Darby bovine kidney (cells); OMK, owl monkey kidney (cells); SF, Spodoptera frugiperda (cells).
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E. De CLERCQ VZV) and that most of these antiherpes agents are pyrimidine nucleoside analogues. This includes the classical antiherpes drugs idoxuridine (IDU, 5-iodo-2'-deoxyuridine) and trifluridine (TFT, 5-trifluoromethyl-2'-deoxyuridine), which are both used as eye drops for the topical treatment of herpetic keratitis, and the newer antiherpes drugs BVDU and FIAC, which offer great promise for the systemic treatment of HSV and VZV infections. Although structurally related to guanosine, ACV could functionally be regarded as a pyrimidine nucleoside analogue to the extent it is recognized as substrate by the HSV-induced dThd-dCyd kinase (Ref. 7).
In the present report I will review the antiviral activity of a wide variety of 5-substitu--ted pyrimidine nucleoside analogues belonging to either of the following classes 2'-deoxyuridine (dUrd, 1-(2-deoxy--D-ribofuranosyl)-uracil), 2' -deoxycytidine (dCyd, 1-(2-deoxy--D-ribofuranosyl)-cytosine) or uracil arabinoside (araU, 1-(8-D-arabinofuranosyl)-uracil). From the whole series of dUrd, dCyd and araU analogues tested, the (E)-5-(2-bromovinyl)derivatives emerged as the most potent and most selective antiherpes agents. BVDU (E)-5-(2-bromovinyl)-dUrd served as the starting material for the synthesis of several sugar-modified analogues and 3'-O-or 5'-O-acyl esters. BVDU has also been the subject of extensive studies aimed at determining its spectrum of amtiviral activity and mechanism of action. It has been explored for its efficacy in the treatment of various HSV and VZV infections in animal models and it has recently been submitted to clinical trials in humans.
5-SUBSTITUTED 2' -DEOXYURIDINES
Among the 5-substituted dUrd derivatives (Fig. 1) . Their 1D50 for HSV1 was only slightly higher than that of the standard antiherpes drug, 5-iodo-dUrd. These compounds were inhibitory to HSV2 at similar concentrations as those required to inhibit HSVi. With the exception of 5-propyl-dUrd, they were also inhibitory to VV. 5-Nitro-dUrd and 5-ethynyl-dUrd interfered with normal cell metabolism (as monitored by incorporation of (1',2'-3H)dUrd or (2-I4cJdUrd into DNA) at a concentration which was 10-to 15-fold lower than the minimal antiviral concentration, thus achieving a "negative" selectivity index. These compounds should therefore be considered as cytotoxic rather than antiviral. In contrast with 5-nitro-dUrd and 5-ethynyl-dUrd, the 5-alkyl-2'-deoxyuridines 5-ethyl-and 5-propyl-dUrd proved quite selective in their antiviral activity.
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). These compounds were also the most potent inhibitors of HSVI replication. Their 1D50 for HSV1 ranged from 0.008 to 0.07 pg/mI, that is roughly 3 orders of magnitude lower than the cytotoxic concentration ( Table 1) . The potent and selective anti-HSVI activity of (E)-5-(2-bromovinyl)-dUrd is critically dependent on the E ("Entgegen" or configuration of the 5-substituent, since (Z)-5-(2-bromovinyl)-dUrd, with bromine in the ("Zusammen" or cis) position, was about 100 times less active against HSV1 than the isomer (Ref. 14).
All (E)-5-(2-X-vinyl)-dUrd derivatives inhibited HSV2 replication at a concentration that was significantly higher than the concentration required to inhibit HSVi replication (Ref. The (E)-5-(2-X-vinyl)-dUrd analogues were even less inhibitory for VV than for HSV2. For (E)-5-(3,3,3-trifluoro-1-propenyl)-dUrd the difference in the ID50 for VV and 1D50 for HSV1 amounted to 5000-fold (Table 1 ). The ratio of ID50 for VV to 1D50 for HSVi can be considered as another reliable parameter for the selectivity of the compounds as anti-HSV1 agents. Of all 5-substituted dUrd analogues tested, (E)-5-(2-bromovinyl)-dUrd emerged as the most potent inhibitor of HSV1 replication, whereas 5-vinyl-dUrd proved the most effective against HSV2. The greatest selectivity was displayed by (E)-5-(2-chlorovinyl)-dUrd.
5-SUBSTITUTED 2' -DEOXYCYTIDINES
The 5-substituted dCyd derivatives (Fig. 2) inhibited HSVi replication at similar or slightly higher concentrations than their dUrd counterparts (Table 2 ). This appeared also to be the case for HSV2 replication. Like the (E)-5-(2-X-vinyl)-dUrd analogues, (E)-5-(2-bromovinyl)-dCyd and (E)-5-(2-iodovinyl)-dCyd discriminated between HSV1 and HSV2, inhibiting HSV2 at a concentration that was about 100-fold higher than the concentration required to inhibit HSV1 replication (Ref. 16). The transition from the dUrd to the dCyd series was accompanied by a significant decrease in anti-VV activity. This decrease in anti-VV activity was particularly striking for 5-nitro-dCyd (Ref. 8) and 5-vinyl-dCyd (Ref. 17), which were 250-to 350-fold less active against vaccinia virus than the corresponding dUrd derivatives.
All 5-substituted dCyd that were examined proved to be selective inhibitors of HSV1 replication. Those compounds that were highly selective antiherpes agents in their dUrd form, i.e. (E)-5-(2-bromovinyl)-dUrd and (E)-5-(2-iodovinyl)-dUrd, retained their selectivity when converted to the dCyd form; and those compounds that were not selective or "negatively" selec-626 E. De CLERCQ tive antiherpes agents in their dUrd form, i.e. 5-nitro-dUrd and 5-ethynyl-dUrd, acquired a significant increase in selectivity upon conversion to the dCyd form. Of all dCyd analogues tested, (E)-5-(2-bromovinyl)-dCyd was the most potent inhibitor of HSV1 replication. It was also the most selective inhibitor. Akin to 5-vinyl-dUrd among the dUrd analogues, 5-vinyldCyd ranked as the most potent inhibitor of HSV2 replication among the dCyd analogues. 
5-SUBSTITUTED URACIL ARABINOSIDES
For a number of 5-substituted dUrd analogues the corresponding 5-substituted araU analogues have been prepared (Fig. 3) . As a rule, the 5-substituted araU analogues were less active against HSV1 than their dUrd counterparts (Table 3) ; thus, (E)-5-(2-bromovinyl)-araU < (E)-
The only exception to this rule is araT (5-methyl-araU) which is a potent inhibitor of HSV replication whereas its dUrd counterpart, dThd, is not.
HO.
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... ... AraT was the only araU analogue which inhibited the replication of VV. Also, araT and 5-vinyl-araU were the only araU analogues showing an appreciable anti-HSV2 activity. However, 5-vinyl-araU proved somewhat less inhibitory to HSV2 than 5-vinyl-dUrd or 5-vinyl-dCyd. The most potent inhibitors of HSV1 replication were, again, the (E)-5-(2-halogenovinyl)derivatives. (E)-5-(2-Bromovinyl)-araU inhibited the replication of HSV1 in P8K cells at a concentration of 0.1 pg/mi, that is about 10-fold higher than the concentration required for (E)-5-(2-bromovinyl)-dUrd to inhibit HSV1 replication in P8K cells. Like (E)-5-(2-bromovinyl)-dUrd, (E)-5-(2-bromovinyl)-araU showed a marked selectivity in its anti-HSVi activity and did not inhibit HSV2 replication unless its concentration was raised to more than 100 times the HSV1-inhibiting concentration. : 5-ethyl--araU
The preceding studies which were all performed in primary rabbit kidney cell cultures revealed that the (E)-5-(2-halogenovinyl)derivatives exceeded all other nucleoside analogues in anti-HSV1 potency and selectivity. From these (E)-5-(2-halogenovinyl)derivatives BVDU could be singled out as the most potent and selective anti-HSV1 agent. As shown in Table 4 , its antiviral activity was not limited to rabbit cells. Its action spectrum extended to various other cell lines of either human, simian, feline or murine origin (Ref. 25). According to the cell line chosen the ID5O of BVDU for HSV1 varied from 0.004 pg/ml (murine f ibroblast cells) to 0.2 g/ml (feline lung cells). A much greater variation of potency was observed for BVaraU which inhibited HSV1 replication in human cells at a concentration of 0.01 pg/ml, while it failed to do so in simian cells at concentrations up to 200 ig/ml. Irrespective of the cell line chosen, BVDU was 10-to 20-fold more active against HSV1 than the standard antiherpes drug IDU. BVDU was also more active than the other selective antiherpes drugs, ACV and FIAC, in human, simian and murine but not feline cells (Ref. 25). BVDU and a selected number of 5-substituted dUrd, dCyd and araU analogues were evaluated for their inhibitory effects on VZV replication in human embryo fibroblasts. From these studies, again, the (E)-5-(2-halogenovinyl)derivatives emerged as the most potent and selective antiviral agents (Ref. 26 & 27) . Three compounds, (E)-5-(2-bromovinyl)-dUrd, (E)-5-(2-iodovinyl)-dUrd and (E)-5-(2-bromovinyl)-araU inhibited VZV replication at an ID5O of 1-2 ng/ml, that is even lower than the ID50 for HSVi replication. Moreover, these compounds did not affect normal cell metabolism (as monitored by incorporation of (1',2'-3H)dThd into DNA) unless they were added at a concentration of 50-100 pg/ml, thus 50,000 times the minimal antiviral concentration (Table 5) . As compared to BVDU, BVDC was 10 times less potent and also ten times less selective as an anti-VZV agent. In turn, araT was 10 times less potent and selective than BVDC, and another ten-fold drop in potency and selectivity was noted for ACV. Thus, ACV appeared to be 1000 times less potent and selective in its anti-VZV activity than BVDU. This is the more remarkable as ACV has been launched as a promising chemotherapeutic agent for the treatment of VZV infections in humans (Ref. The activity spectrum of BVDU is not restricted to HSV1 and VZV but extends to several other herpesviruses such as pseudorabies virus (PRy), bovid herpesvirus type I (BHV1), simian varicella virus (SVV), herpesvirus saimiri (HVS) and nuclear polyhedrosis virus (NPV) ( Table  6 ) (Ref. 3, 4, 27 & 31-35), HVS being a simian lymphotropic virus and NPV, an invertebrate pathogenic virus. BVDU inhibited the replication of PRy, BHVI and SVV at a concentration of 0.01 pg/ml, that is the same concentration as that required for inhibition of HSV1 replication. Although ACV proved effective against HSV1 and HSV2 at a concentration of 0.04 pg/ml, it had no effect on the replication of PRy, BHV1, HVS and NPV (Ref. 31, 32, 34 & 35) . This lack of activity may be related to the fact that the dThd kinase encoded by PRV, BHV1, HVS and NPV is devoid of dCyd kinase activity and that ACV needs this dCyd kinase activity to express its selective antiviral action. The dThd kinase encoded by HSV1 and HSV2 has an associated dCyd kinase activity and this would explain why ACV is specifically active against these viruses. Since no dCyd kinase activity is induced in PRy-, BHV1-, HVS-and NPV-infected cells, ACV cannot be phosphorylated in these cells, and, consequently, fail to interact with the virus replicative cycle. BVDU would still be effective under these conditions, since its phosphorylation depends on the virus-induced dThd kinase rather than dCyd kinase. 
SUGAR-MODIFIED DERIVATIVES OF (E)-5-(2-BROMOVINYL)-dUrd
With (E)-5-(2-bromovinyl)-dUrd (BVDU) as starting material several sugar-modified derivatives (Fig. 4) were prepared in attempts to develop, if at all possible, a compound with superior anti-HSV2 activity. Of this series of BVDU derivatives, only three compounds, 3'-azido-BVDU, 3'-amino-BVDU and 5'-iodo-BVDU, exhibited an appreciable antiherpes activity (Table 7 ) (Ref. 18 & 36). These compounds inhibited HSV1 replication at a concentration of 1, 0.1 and 1 pg/ml, respectively. None of the new sugar-modified derivatives of BVDU was more active against HSV2 than the parent compound. For 3'-amino-BVDU the ratio of IDSO for HSV2 to ID5O for HSVj amounted to 250, which implies that this compound, like BVDU and the other (E)-5-(2-halogenovinyl)substituted dUrd, dCyd and araU analogues could be proposed as useful markers to discriminate between HSV1 and HSV2. 3'-Amino-BVDU could be regarded as a truly selective inhibitor of HSV1. This was further attested by its lack of anti-VV activity. Even at a concentration of 200 pg/ml, that is 2000 times higher than the ID5O for HSV1, 3'-amino-BVDU failed to inhibit the replication of vaccinia virus. So did most other sugar-modified derivatives of BVDU. 
3'-O-AND 5'-O-ESTER DERIVATIVES OF (E)-5-(2-BROMOVINYL)-dUrd
Several 3'-O-, 5'-O-and 3',5'-di-O-acyi esters of (E)-5-(2-bromovinyl)-dUrd (BVDU) (Fig. 5 ) have been prepared, principally aimed at changing the pharmacological properties (i.e. solubility in aqueous or lipid medium) of BVDU. With the exception of the highly lipophilic esters, 5'-0-palmitoyl-BVDU, 5'-O-adamantanocarbonyl-BVDU and 3' ,5 '-di-O-pivaloyl-BVDU, all BVDU esters inhibited the replication of HSV1 at an 1D50 which was only slightly higher than the IDSO of the parent compound (Table 8 ). This suggests that under the conditions used the BVDU esters were readily hydrolyzed to release the free nucleoside. The ID50 of the BVDU esters for HSV2 was 100-to 500-fold higher than the 1D50 for HSV1, which, again, indicated that their antiviral activity resided in the release of free BVDU and that the BVDU esters, like BVDU itself, could serve as useful markers to differentiate HSV1 from HSV2 strains. For some BVDU esters the anti-VV activity was comparable to that of BVDU; for others; espe- cially the lipophilic ones, no activity was noted against VV. It would now seem mandatory to examine whether any of the 3'-O-, 5'-O-or 3',5'-di-O-acyl esters of BVDU offers a greater therapeutic benefit than the parent compound in animal model infections. Average values for 3 HSV1 strains and 3 HSV2 strains.
Data taken from De Clercq et al. (37).
MECHANISM OF ANTIVIRAL ACTION OF (E)-5-(2-BROMOVINYL)-dUrd ANDOTHER (E)-5-(2-BROMOVINYL) DERIVATIVES -
The mode of action of (E)-5-(2-bromovinyl)-dUrd has been elucidated to a considerable extent. It is essentially based on three principles : (i) a specific phosphorylation by the virus-induced dThd kimase, (ii) a greater inhibition of viral DNA polymerase than cellular DNA polymerase by BVDU 5'-triphosphate (BVDUTP), and (iii) the incorporation of the latter into viral DNA (Fig. 6 ). The target for the antiviral action of BVDU may be viral DNA synthesis or viral DNA itself. Indeed, the 5'-triphosphate of BVDU has been shown to inhibit HSV1 DNA polymerase to a significantly greater extent than the cellular DNA polymerases a, and y (Ref. 41) . Moreover, BVDUTP can substitute for dTTP as an alternate substrate for both viral and cellular DNA polymerases (Ref. 42 & 43) , and thus be incorporated into DNA. BVDU is not incorporated into DNA of uninfected mouse (BALB/3T3) or monkey (Vero) cells (Ref. 42 & 44) , most likely because it is not phosphorylated in these cells. However, BVDU is incorporated into DNA of HSV1-infected cells. If added at a supra-optimal concentration (10 pg/ml), it is incorporated into both viral and cellular DNA of HSV1-infected Vero cells (Ref. 42) . If added at optimal concentrations (0.03-0.1 pglml), it is incorporated into viral DNA only (Ref. 45 ). The extent of incorporation correlates closely with the reduction in virus yield, and since the BVDU-substituted HSV1 DNA is liable to single-strand breakage (Ref. 45) , the incorporation of BVDU into viral DNA may well be the decisive factor in the antiviral action of the compound.
Although the mechanism of action of the other (E)-5-(2-halogenovinyl)derivatives, i.e. (E)-5-(2-bromovinyl)-dCyd (BVDC), (E)-5-(2-bromovinyl)-araU (BVaraU) and 3' -amino-BVDU, has not been explored in detail, it is conceivable that they act in a similar manner as BVDU (Fig. 6) . Therefore BVDC should first be deaminated at either the nucleoside or nucleotide level. An important difference in the mode of action of BVDU and BVaraU concerns their incorporation into DNA : while BVDUTP is recognized by DNA polymerase as an alternate substrate and is incorporated into DNA probably within the interior of the DNA chain, BVaraUTP does not serve as an efficient substrate for DNA polymerase, although it could be incorporated at the 3'-end of the DNA chain, thereby acting as a chain terminator (Ref. 46 & 47) . Whether 3'-NH2-BVDUTP is incorporated into DNA has not been determined yet. Unlike BVDUTP, BVaraUTP and 3'-NH2-BVDUTP do'not inhibit HSV1 DNA polymerase to a greater extent than cellular DNA polymerase a (Ref. 47 & 48) . One may postulate, therefore, that the selectivity of BVaraU and 3'-NH2-BVDU as antiherpes agents depends primarily on a specific phosphorylation by the viral dThd kinase. This would be consistent with the high affinity of BVaraU for HSV1 dThd kinase (Ki = 0.94 iiM, as compared to > 100 pM for cytosol dThd kinase) (Ref. 49) . Whether the FISV1 dThd carries on the phosphorylation of BVaraU and 3'-NH2-BVDU to the 5'-diphosphate stage, as shown for BVDU, remains to be established.
EFFICACY OF (E)-5-(2-BROMOVINYL)-dUrd IN ANIMAL MODEL INFECTIONS
From the (E)-5--(2--halogenovinyl)derivatives, (E)-5-(2-bromovinyl)-dUrd (BVDU) was chosen for further evaluation in experimental animal models, i.e., cutaneous and intracerebral HSV1 infection in mice, HSV1 keratitis and uveitis (iritis) in rabbits, SVV infection in monkeys and PRV infection in pigs (Table 9) In African green monkeys infected with SVV, BVDU eliminated all manifestations of the disease, including viremia, rash and anorexia, when given at a dosage as low as 15 mg/kg/day; but, even if the dosage was lowered to I mg/kg/day, BVDU conferred a slight inhibitory effect on the disease (Ref. 
EFFICACY OF (E)-5-(2-BROMOVINYL)-dUrd IN HUMANS
Prompted by the efficacy of (E)-5-(2-bromovinyl)-dUrd (BVDU) in animal model infections and its apparent freedom of toxicity at therapeutically effective doses, clinical trials have been initiated to assess the usefulness of BVDU in the topical and systemic (oral) treatment of RSV1 and VZV infections in humans (Table 10 ). The drug proved highly efficacious, as 0.1 % eye drops, in the topical treatment of patients with different forms of herpetic keratitis, i.e. dendritic corneal ulcers, geographic corneal ulcers and stromal disease (Ref. 63 & 64) . Most of these patients had first been treated with topical IDU or ara-A (vidarabine, 9--Darabinofuranosyladenine), albeit unsuccessfully, before BVDU treatment was started. They all responded rapidly to BVDU therapy. No toxic side effects, whether local or systemic, were noted in any of the patients treated with EVDU. BVDU was also administered perorally at a dosage of 7.5-15 mg/kg/day for 5 days to cancer patients who had developed a severe mucocutaneous herpes simplex or herpes zoster infection as the consequence of an intensive anticancer chemotherapy or radiotherapy (Ref. 65, 68 & 69) . In these patients BVDU caused a rapid healing of the herpes lesions : pain and fever (if present) subsided, no new lesions formed and existing lesions regressed within the first few days after BVDU treatment was started. Similar promising results have been obtained with oral BVDU (combined with BVDU eye drops) in the treatment of patients suffering from ophthalmic zoster (Ref. 64 & 66) . Equally successful were results of oral BVDU treatment in leukemic children with severe varicella or zoster (Ref. 67) . All children recovered promptly from their varicella-zoster episode. Neither adults nor children showed any sign of drug toxicity for liver, kidney, bone marrow or any other organ.
It should be emphasized that the clinical studies that have so far been conducted with BVDU (Ref. [63] [64] [65] [66] [67] [68] [69] were all uncontrolled. Obviously, these studies should be extended to doubleblind placebo-controlled trials before the therapeutic usefulness of BVDU could be fully substantiated. 
